FLUOGUIDE A/S DK -1 - Asset Resilience Ratio
FLUOGUIDE A/S DK -1 (96X) has an Asset Resilience Ratio of 34.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of FLUOGUIDE A/S DK -1 for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2025–2025)
This chart shows how FLUOGUIDE A/S DK -1's Asset Resilience Ratio has changed over time. See 96X net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down FLUOGUIDE A/S DK -1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see FLUOGUIDE A/S DK -1 (96X) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.02 Million | 34.0% |
| Total Liquid Assets | €30.02 Million | 34.00% |
Asset Resilience Insights
- Very High Liquidity: FLUOGUIDE A/S DK -1 maintains exceptional liquid asset reserves at 34.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
FLUOGUIDE A/S DK -1 Industry Peers by Asset Resilience Ratio
Compare FLUOGUIDE A/S DK -1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 35.56% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for FLUOGUIDE A/S DK -1 (2025–2025)
The table below shows the annual Asset Resilience Ratio data for FLUOGUIDE A/S DK -1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.00% | €30.02 Million ≈ $35.09 Million |
€88.29 Million ≈ $103.22 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more